MBX Biosciences, Inc. Payments of Stock Issuance Costs
MBX Biosciences, Inc. (MBX) reported Payments of Stock Issuance Costs of $505.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2026-08-06
- MBX Biosciences, Inc. payments of stock issuance costs for the quarter ending 2026-06-30 was $127.00K.
- MBX Biosciences, Inc. payments of stock issuance costs for the quarter ending 2026-03-31 was $378.00K.
- MBX Biosciences, Inc. payments of stock issuance costs for the quarter ending 2025-12-31 was $517.00K, a 58.10% increase year-over-year.
- MBX Biosciences, Inc. payments of stock issuance costs for the quarter ending 2025-09-30 was $254.00K, a 86.76% decline year-over-year.
- MBX Biosciences, Inc. payments of stock issuance costs for fiscal 2025 was $771.00K, a 81.02% decline from fiscal 2024.
- MBX Biosciences, Inc. payments of stock issuance costs for fiscal 2024 was $4.06M.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $127.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $505.00K 10-Q · filed 2026-08-06 | $1.02M derived: sum of 3 quarters · filed 2026-08-06 | $1.28M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $378.00K 10-Q · filed 2026-05-07 | $895.00K derived: sum of 2 quarters · filed 2026-05-07 | $1.15M derived: sum of 3 quarters · filed 2026-05-07 | $1.15M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $517.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $771.00K derived: sum of 2 quarters · filed 2026-03-12 | $771.00K derived: sum of 3 quarters · filed 2026-08-06 | $771.00K 10-K · filed 2026-03-12 |
| 2025-09-30 | $254.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $254.00K derived: sum of 2 quarters · filed 2026-08-06 | $254.00K 10-Q · filed 2025-11-06 | $581.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | $327.00K derived: sum of 3 quarters · filed 2026-08-06 | $2.25M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | $327.00K derived: sum of 2 quarters · filed 2026-05-07 | $2.25M derived: sum of 3 quarters · filed 2026-05-07 | $4.06M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $327.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $2.25M derived: sum of 2 quarters · filed 2026-03-12 | $4.06M derived: sum of 3 quarters · filed 2026-03-12 | $4.06M 10-K · filed 2026-03-12 |
| 2024-09-30 | $1.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $3.73M derived: sum of 2 quarters · filed 2025-11-06 | $3.73M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $1.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $1.82M 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $6.00K 10-Q · filed 2025-05-12 | |||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |